Selsym Biotech Inc.
Cary, NC
- UEI
- G522J2NEDHD2
- CAGE
- 8JGX8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 101 Linecrest Ct, Cary, NC 27518, USA
- Website
- selsymbio.com
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Symclot: synthetic platelet mimetic particles for augmenting hemostasis in patients requiring extracorporeal support | Defense Health Agency | $1,996,885 | |
| Symheal: a novel therapy for treating non-healing diabetic ulcers - project summary non-healing wounds are a significant… | National Institute of Diabetes and Digestive and Kidney Diseases | $458,948 | |
| Increasing efficiency of sdfv production in a tobacco-based system for synthetic platelet design - project summary… | National Heart Lung and Blood Institute | $258,501 | |
| Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma - project summary… | National Heart Lung and Blood Institute | $1,019,512 |
About Selsym Biotech Inc.
Selsym Biotech Inc. is a woman-owned small business and for-profit corporate entity. It is involved in developing synthetic platelet mimetic technologies for applications in treating bleeding, clotting disorders, and wound healing.
Selsym Biotech has received several federal grants to support its work on synthetic platelet-like particles (PLPs) and related technologies. A recent $1.9 million award from the Defense Health Agency funds development of PLPs called SYMCLOT for augmenting hemostasis in patients requiring extracorporeal support like those with battlefield injuries. The National Institute of Diabetes and Digestive and Kidney Diseases provided $458,948 to develop SYMHEAL, PLPs combined with growth factors for treating non-healing diabetic ulcers. The National Heart, Lung and Blood Institute awarded $258,501 to optimize antibody fragment yield in a plant expression system to scale up PLP production, and $1 million to evaluate long-term PLP stability and maximum tolerated dose for trauma care. These grants demonstrate Selsym's extensive research across military, emergency medicine, and diabetic wound healing applications leveraging its core synthetic platelet technology under programs like Military Medical Research and Development, Extramural Research in Diabetes and Kidney Diseases, and Cardiovascular Sciences.
Quick answers
What is Selsym Biotech Inc.'s UEI?
Selsym Biotech Inc.'s Unique Entity ID (UEI) in SAM.gov is G522J2NEDHD2.
What is Selsym Biotech Inc.'s CAGE code?
Selsym Biotech Inc.'s CAGE code is 8JGX8.
What is Selsym Biotech Inc.'s primary NAICS code?
Selsym Biotech Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Selsym Biotech Inc. located?
Selsym Biotech Inc.'s physical address in SAM.gov is 101 Linecrest Ct, Cary, NC 27518, USA.
Is Selsym Biotech Inc. registered in SAM.gov?
Yes. Selsym Biotech Inc.'s SAM.gov registration is active through May 31, 2027.
What is Selsym Biotech Inc.'s most recent federal award?
Selsym Biotech Inc.'s most recent federal grant award is Symclot: synthetic platelet mimetic particles for augmenting hemostasis in patients requiring extracorporeal support (HT94252310977), from Defense Health Agency, on September 30, 2023.
On GovTribe
See Selsym Biotech Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors